> MEDIA   Overview   Press Releases   Media Stories   Download Center   Video Gallery   Photo Gallery   Media Contacts

Press Releases 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005     March 2020 09 Mar U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Bevacizumab for Review   February 2020 27 Feb Company Statement: Biocon's Small Molecules API Manufacturing Facility Completes Post-Approval and GMP U.S. FDA Inspection 22 Feb Company Statement: Biocon's Insulin Manufacturing Facility in Malaysia Completes U.S. FDA (PAI) Inspection 20 Feb Kiran Mazumdar-Shaw Named EY Entrepreneur of the Year India 2019   January 2020 27 Jan Company Statement: Biocon's Small Molecules API Manufacturing Facility Completes Pre-Approval and GMP U.S. FDA inspection 23 Jan Biocon Q3FY20 Earnings Revenue at Rs 1,784 Cr, Up 14%; EBITDA at Rs 480 Cr, Up 18%; Net Profit (before exceptional item) at Rs 225 Cr, Up 6% 20 Jan Company Statement: Biocon's Oral Solid Dosage Manufacturing Facility Completes Pre-Approval U.S. FDA lnspection with Zero Observations 19 Jan Kiran Mazumdar-Shaw Honoured with Order of Australia, Australia's Highest Civilian Honour 06 Jan True North to Invest Rs 536.25 Crore in Biocon Biologics for 2.44% Stake 06 Jan Biocon Biologics Appoints M.B. Chinappa as Chief Financial Officer

Biocon Businesses Recommended sites Biocon on     Home About Us Investor Relations Media Relations Careers Site Map Contact Us Our Growth Accelerators Fact Sheet Branded Formulations Biopharmaceuticals Research Services Active Discovery Program ABLE Karnataka Vision Group on BT Syngene International Biocon Academy                   Report adverse event/side effects and product complaints               * Disclaimer            © 2018, Biocon. All Rights Reserved